mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

MiR-100-5p, miR-199a-3p and miR-199b-5p induce autophagic death of endometrial carcinoma cell through targeting mTOR.

Cai, J., Zhang, Y., Huang, S., Yan, M., Li, J., Jin, T., & Bao, S. (2017) · PubMed Central · Cited by 15

Cancer metabolism: targeting cancer universality

Kim, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0551-5 · Cited by 14

Role of adiponectin in osteoarthritis

Feng, X., Xiao, J., & Bai, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.992764 · Cited by 15

Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

Cai, W. L., Shu, L.-Z., Liu, D.-J., Zhou, L., Wang, M.-M., & Deng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145082 · Cited by 15

Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer

Lu, Z., Wang, T., Wang, L., & Ming, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102387 · Cited by 14

Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.

Li, N., Zhong, M., & Song, M. (2012) · Europe PMC (PubMed Central) · Cited by 14

mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View

Oda, K., Ikeda, Y., Kawana, K., Osuga, Y., & Fujii, T. (2015) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-014-0103-x · Cited by 14

Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer

Laudański, P., Kowalczuk, O., Klasa-Mazurkiewicz, D., Milczek, T., Rysak-Luberowicz, D., Garbowicz, M., Baranowski, W., Charkiewicz, R., Szamatowicz, J., & Chyczewski, L. (2011) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.2011.0044 · Cited by 14

Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: Confocal microscopy characterization and immunohistochemical validation of PP-mTORSer2481 as a novel high-contrast mitosis marker in breast cancer core biopsies

Menendez (2009) · International Journal of Oncology · doi:10.3892/ijo_00000481 · Cited by 14

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors

Stepanova, V. V., Дергилев, К. В., Holman, K. R., Parfyonova, Y. V., Цоколаева, З. И., Teter, M., Atochina‐Vasserman, E. N., Volgina, A., Zaitsev, S. V., Lewis, S. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.799593 · Cited by 13

Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model

Parada, B., Reis, F., Figueiredo, A., Nunes, P., Teixeira‐Lemos, E., Garrido, P., Sereno, J., Pinto, R. M. A., Cunha, M. F., Neto, P., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09326.x · Cited by 14

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines

Martin, B., Edeline, J., Patard, J., Oger, E., Jouan, F., Boulanger, G., Zerrouki, S., Vigneau, C. M., & Rioux-Leclercq, N. C. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1162-x · Cited by 14

Inhibition of mTOR Reduces Anal Carcinogenesis in Transgenic Mouse Model

Sun, Z., Zhang, L., Zhang, W. J., Hall, B., Bian, Y., & Kulkarni, A. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074888 · Cited by 14

Molecular Targeted Therapy of Hepatocellular Carcinoma

Terry, K., & Copur, M. S. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.42a052 · Cited by 14

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

Rubenstein, M., Tsui, P. T., & Guinan, P. (2009) · Medical Oncology · doi:10.1007/s12032-009-9254-4 · Cited by 14

Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models

Hebron, M. L., Algarzae, N. K., Lonskaya, I., & Moussa, C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.01.009 · Cited by 14

A case of lymphangioleiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus

Suzuki, K., Nagasaka, K., Oda, K., Abé, H., Maeda, D., Matsumoto, Y., Arimoto, T., Kawana, K., Fukayama, M., Osuga, Y., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2413-z · Cited by 14

Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux

Ilina, E. I., Armento, A., Sanchez, L. G., Reichlmeir, M., Braun, Y., Penski, C., Capper, D., Sahm, F., Jennewein, L., Harter, P. N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18747 · Cited by 13

PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo

Ye, X., Ruan, J., Huang, H., Huang, W., Zhang, Y., & Zhang, F. (2020) · Aging · doi:10.18632/aging.103221 · Cited by 14

Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein

Ravaud, A., Bernhard, J.-C., Gross-Goupil, M., Digue, L., & Ferriere, J.-M. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1069 · Cited by 14

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma

Cho, J., Lee, J., Kim, J.-S., Kim, S. T., Lee, S., Kim, S. Y., Ha, S. Y., Park, C.-K., & Lim, H. Y. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.08.009 · Cited by 14

Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles

Shin, H. J., Jo, M. J., Jin, I. S., Park, C., Kim, J., & Shin, D. H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s315782 · Cited by 13

GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms

Jin, L., Zhang, W., Yao, M.-Y., Tian, Y., Xue, B., & Tao, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00911-y · Cited by 13

Fine-tuning AMPK in physiology and disease using point-mutant mouse models

Ashraf, N., & Nostrand, J. L. V. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050798 · Cited by 14

Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway

Lyo, D., Xu, L., & Foster, D. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.148 · Cited by 13

Treatment of Metastatic Renal Cell Carcinoma

Richter, I., & Dvořák, J. (2018) · Klinicka onkologie · doi:10.14735/amko2018110 · Cited by 13

CCK-independent mTORC1 activation during dietary protein-induced exocrine pancreas growth

Crozier, S. J., Sans, M. D., Wang, J. Y., Lentz, S. I., Ernst, S. A., & Williams, J. A. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00445.2009 · Cited by 13

CC-223 inhibits human head and neck squamous cell carcinoma cell growth

Wang, J., Jin, X., Zhang, X., & Li, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.168 · Cited by 13

BMP-2 upregulates the AKT/mTOR pathway in breast cancer with microcalcification and indicates a poor prognosis

Wang, S., Gu, M., Jiang, H., & Zheng, X. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02248-y · Cited by 13

Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer

Chen, A. Y.-C., Chen, L., Al‐Qaisi, A., Romond, E. H., Awasthi, M., Kadamyan, V., & Massarweh, S. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.002 · Cited by 13

Perspectives in drug development for metastatic renal cell cancer

Basu, B., & Eisen, T. G. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0149-2 · Cited by 13

mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside

Akhavan, D., & Mischel, P. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_5 · Cited by 13

Targeting intracellular galectins for cancer treatment

Nehmé, R., & St‐Pierre, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269391 · Cited by 13

Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis

Oskouie, A. A., Ahmadi, M. S., & Taherkhani, A. (2022) · MicroRNA · doi:10.2174/2211536611666220124115445 · Cited by 12

Current understanding of gliomagenesis: from model to mechanism

Luo, J., Junaid, M., Hamid, N., Duan, J., Yang, X., & Pei, D. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.77287 · Cited by 15

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways

Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Al-kaabi, M. M., Hameed, M. R., Abduljabbar, R. F., Muftah, A. A., Nolan, C. C., Green, A. R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3308-4 · Cited by 13

A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway

Hsu, J., Liu, S., Lee, C.-C., Hsu, L., Ho, Y., Huang, H., & Guh, J. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0998-9 · Cited by 12

Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy

Dobashi, Y. (2010) · Frontiers in bioscience · doi:10.2741/3815 · Cited by 12

Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair

Udayakumar, D., PANDITA, R. K., Horikoshi, N., Liu, Y., Liu, Q., Wong, K., Hunt, C. R., Gray, N. S., Minna, J. D., Pandita, T. K., et al. (2016) · Radiation Research · doi:10.1667/rr14373.1 · Cited by 12

Inhibition of mammalian target of rapamycin activation in the rostral anterior cingulate cortex attenuates pain-related aversion in rats

Lu, B., Jiang, J., Sun, J., Xiao, C., Meng, B., Zheng, J., Li, X., Wang, R., Wu, G., & Chen, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.011 · Cited by 12

Preclinical study of CC223 as a potential anti-ovarian cancer agent

Jin, Z., Niu, H., Wang, X., Zhang, L., Wang, Q. L., & Yang, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17753 · Cited by 12

Combination with miR‐124a improves the protective action of BMSCs in rescuing injured rat podocytes from abnormal apoptosis and autophagy

Sun, J., Lv, J., Zhang, W., Li, L., Lv, J., Geng, Y., & Yin, A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26771 · Cited by 12

Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo

Xing, Z., Wang, Y., Cheng, L., Chen, J., He, X., & Xing, W. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494185 · Cited by 12

Targeting mTORC 1/2 with OSI ‐027 inhibits proliferation and migration of keloid keratinocytes

Chen, J., Liu, K., Liu, Y., Wang, X., & Zhang, Z. (2019) · Experimental Dermatology · doi:10.1111/exd.13882 · Cited by 12

Role of adherens junctions and apical-basal polarity of neural stem/progenitor cells in the pathogenesis of neurodevelopmental disorders: a novel perspective on congenital Zika syndrome

Bustamante, F. A., Miró, M. P., Velásquez, Z. D., Molina, L., Ehrenfeld, P., Rivera, F. J., & Bátiz, L. F. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.014 · Cited by 12

Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma

McGregor, B. A., Xie, W., Adib, E., Stadler, W. M., Zakharia, Y., Alva, A., Michaelson, M. D., Gupta, S., Lam, E. T., Farah, S., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00448 · Cited by 12

An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth

Chen, F., Zhao, H., Li, C., Li, P., & Zhang, Q. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01082-6 · Cited by 12

Molecular Mechanisms of Apoptosis in Prostate Cancer

Lorenzo, P. I., Arnoldussen, Y. J., & Saatcioglu, F. (2007) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v13.i1.10 · Cited by 12

DNA repair, insulin signaling and sirtuins: at the crossroads between cancer and aging

Mostoslavsky, R. (2008) · Frontiers in bioscience · doi:10.2741/3203 · Cited by 11

Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again

Abraham, R. T. (2009) · F1000 Biology Reports · doi:10.3410/b1-8 · Cited by 12

Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity

Liu, Y., Xia, Q., & Fang, L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.025 · Cited by 12

Phosphorylation of serine/arginine‐rich splicing factor 1 at tyrosine 19 promotes cell proliferation in pediatric acute lymphoblastic leukemia

Xu, L., Zhang, H., Mei, M., Du, C., Huang, X., Li, J., Wang, Y., Bao, S., & Zheng, H. (2018) · Cancer Science · doi:10.1111/cas.13834 · Cited by 12

Live Fast, Die Young: New Lessons in Mammalian Longevity

Cox, L. S. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0894 · Cited by 12

A Hippo “AKT” Regulates Cardiomyocyte Proliferation

Xiao, F., Kimura, W., & Sadek, H. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.305325 · Cited by 12

p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer

de Kort, W. W. B., de Ruiter, E. J., Haakma, W. E., Driehuis, E., Devriese, L. A., van Es, R. J. J., & Willems, S. M. (2023) · Head and Neck Pathology · doi:10.1007/s12105-023-01576-4 · Cited by 11

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

Xu, Z., Liu, L., Jiang, W., Qiu, Y., Zhang, B., Cheng, J., Luo, J., Guo, J., & Xu, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009963 · Cited by 11

Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma

Pracht, M., & Berthold, D. (2014) · Progress in tumor research · doi:10.1159/000355906 · Cited by 11

Clinical significance of pmTOR expression in endometrioid endometrial carcinoma

Choi, C. H., Lee, J.-S., Kim, S. R., Kim, T., Lee, J., Kim, B., & Bae, D. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.07.038 · Cited by 11

Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer

Wiesweg, M., Reis, H., Köster, T., Goetz, M., Worm, K., Herold, T., Paul, A., Dechêne, A., Schumacher, B. M., Markus, P. M., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.003 · Cited by 11

Polycystin‐1 regulates cell proliferation and migration through AKT/mTORC2 pathway in a human craniosynostosis cell model

Katsianou, M. A., Papavassiliou, K. A., Gargalionis, A. N., Agrogiannis, G. D., Korkolopoulou, P. A., Panagopoulos, D., Themistocleous, M. S., Piperi, C., Basdra, E. K., & Papavassiliou, A. G. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17266 · Cited by 10

The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer

Vanhevel, J., Verlinden, L., Loopmans, S., Doms, S., Janssens, I., Bevers, S., Stegen, S., Wildiers, H. P. M. W., & Verstuyf, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.886238 · Cited by 11

Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy

Cayo, Á., Venturini, W., Rebolledo-Mira, D., Moore‐Carrasco, R., Herrada, A. A., Nova‐Lamperti, E., Valenzuela, C. A., & Brown, N. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119284 · Cited by 11

Rapamycin-Resistant Poly (ADP-Ribose) Polymerase-1 Overexpression Is a Potential Therapeutic Target in Lymphangioleiomyomatosis

Sun, Y., Gallacchi, D. A., Zhang, E. Y., Reynolds, S. B., Robinson, L., Malinowska, I. A., Chiou, T. T., Pereira, A. M., Li, C., Kwiatkowski, D. J., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0033oc · Cited by 11

LOW GRADE GLIOMAS

Shih, C., Ekoma, S., Ho, C., Pradhan, K. R., Hwang, E., Jakacki, R. I., Fisher, M., Kilburn, L., Horn, M., Vézina, G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos092 · Cited by 11

Protein Translation and Signaling in Human Eosinophils

Esnault, S. J., Shen, Z.-J., & Malter, J. S. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00150 · Cited by 12

Cancer Metabolism: a Hope for Curing Cancer

Kim, S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.300 · Cited by 11

Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent

Wang, W., Lidong, L., Wang, Y., Li, H., Suo, Z., Long, K., & Tang, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1470733 · Cited by 11

High p‐mTOR expression is associated with recurrence and shorter disease‐free survival in atypical meningiomas

Barresi, V., Lionti, S., Rocca, L. L., Caliri, S. L., & Caffo, M. (2018) · Neuropathology · doi:10.1111/neup.12524 · Cited by 11

EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma

Palomero, L., Bodnar, L., Mateo, F., Herranz, C., Espín, R., García-Varelo, M., Jesiotr, M., Ponce, G. R. D. G., Casanovas, O., Lopez, J. I., et al. (2020) · Cancers · doi:10.3390/cancers12020300 · Cited by 11

Splicing machinery genomics events in acute myeloid leukaemia (AML): in search for therapeutic targets, diagnostic and prognostic biomarkers.

Dlamini, Z., Shoba, B., & Hull, R. (2020) · PubMed Central · Cited by 10

Single cell cytometry of protein function in RNAi treated cells and in native populations

LaPan, P., Zhang, J., Pan, J., Hill, A., & Haney, S. A. (2008) · BMC Cell Biology · doi:10.1186/1471-2121-9-43 · Cited by 11

A Rare Soft Tissue Tumor Masquerading as a Parathyroid Adenoma in a Patient with Birt-Hogg-Dubé Syndrome and Multiple Cervical Endocrinopathies

Mikesell, K. V., Kulaylat, A. N., Donaldson, K. J., Saunders, B., & Crist, H. S. (2014) · Case Reports in Pathology · doi:10.1155/2014/753694 · Cited by 11

Chemopreventive Effect of Dietary Glutamineon Colitis-Associated Colorectal Cancer Is Associated with Modulation of the DEPTOR/mTOR Signaling Pathway

Tian, Y., Wang, K., Fan, Y., Wang, Y., Sun, L., Wang, L., Wang, J., Wang, Z., Li, J., Ye, Y., et al. (2016) · Nutrients · doi:10.3390/nu8050261 · Cited by 12

Liver Tumors Segmentation Using 3D SegNet Deep Learning Approach

Nallasivan, G., Ramachandran, V., Alroobaea, R., & Almotiri, J. (2022) · Computer Systems Science and Engineering · doi:10.32604/csse.2023.030697 · Cited by 10

Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer

Khan, I. R., Sadida, H. Q., Hashem, S., Singh, M. K., Macha, M. A., Akil, A. S. A.-S., Khurshid, I., & Bhat, A. A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116873 · Cited by 12

How lactate affects immune strategies in lymphoma

Zhou, Y., Lou, J., Yuqin, T., Ding, J., Wang, X., & Tang, B. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1480884 · Cited by 11

Treatment Algorithms for Hormone Receptor–Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents

Johnston, S. R. D., & Schiavon, G. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e28 · Cited by 10

Sunitinib for Metastatic Renal Cell Carcinoma

Mukherji, D., Larkin, J., & Pickering, L. M. (2010) · Future Oncology · doi:10.2217/fon.10.94 · Cited by 10

Metabolic Regulation of Thymic Epithelial Cell Function

Semwal, M. K., Jones, N. E., & Griffith, A. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636072 · Cited by 11

Curcumol β-cyclodextrin inclusion complex enhances radiosensitivity of esophageal cancer under hypoxic and normoxic condition

Su, M., Ren, X., Du, D., He, H., Zhang, D., Xie, R., Deng, X., Zou, C., & Zou, H. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01446-7 · Cited by 10

Fission Yeast TOR and Rapamycin

Weisman, R. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)27013-0 · Cited by 10

Artocarpin Induces Apoptosis in Human Cutaneous Squamous Cell Carcinoma HSC-1 Cells and Its Cytotoxic Activity Is Dependent on Protein-Nutrient Concentration

Hu, S. C., Lin, C., Cheng, H., Chen, G., Lee, C., & Yen, F. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/236159 · Cited by 10

Molecular targets for therapeutic interventions in human papillomavirus-related cancers (Review)

de Castro (2010) · Oncology Reports · doi:10.3892/or_00001001 · Cited by 10

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent

Xiong, Z., Zang, Y., Zhong, S., Zou, L., Wu, Y., Liu, S., Fang, Z., Shen, Z., Ding, Q., & Chen, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15620 · Cited by 10

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activityin vitroandin vivo

Yin, G., Fan, J., Zhou, W., Ding, Q., Zhang, J., Wu, X., Tang, P., Zhou, H., Wan, B., & Yin, G. (2017) · Oncotarget · doi:10.18632/oncotarget.18303 · Cited by 10

Systems Challenges of Hepatic Carcinomas: A Review

Madduru, D., Ijaq, J., Dhar, S., Sarkar, S., Poondla, N., Das, P. S., Vásquez, S., & Suravajhala, P. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.05.002 · Cited by 10

Identification of DNA methylation prognostic signature of acute myelocytic leukemia

Zhang, H., Song, G., Song, G., Li, R., Gao, M., Ye, L., & Zhang, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199689 · Cited by 10

β-Barrel outer membrane proteins suppress mTORC2 activation and induce autophagic responses

Chaudhary, A., Kamischke, C., Leite, M., Altura, M. A., Kinman, L., Kulasekara, H. D., Blanc, M.-P., Wang, G., Terhorst, C., & Miller, S. I. (2018) · Science Signaling · doi:10.1126/scisignal.aat7493 · Cited by 10

The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy

Guo, N., Liu, S., Bow, L. M., Cui, X., Zhang, L., Xu, S., Lu, L., & Tian, J. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1577257 · Cited by 11

WinBinVec: Cancer-Associated Protein-Protein Interaction Extraction and Identification of 20 Various Cancer Types and Metastasis Using Different Deep Learning Models

Abdollahi, S., Lin, P., & Chiang, J.-H. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3093441 · Cited by 10

A Synopsis of Signaling Crosstalk of Pericytes and Endothelial Cells in Salivary Gland

Cucu, I., & Nicolescu, M. I. (2021) · Dentistry Journal · doi:10.3390/dj9120144 · Cited by 12

Evaluation of the Nutrient-Sensing mTOR Pathway

Hong, S., Mannan, A. M., & Inoki, K. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-430-8_3 · Cited by 9

Chemistry and Pharmacology of Rapamycin and Its Derivatives

Abraham, R. T., Gibbons, J. J., & Graziani, E. I. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)27017-8 · Cited by 10

Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?

Kim, W. (2015) · International Neurourology Journal · doi:10.5213/inj.2015.19.2.55 · Cited by 11

Characterization of p70 S6 kinase 1 in early development of mouse embryos

Xu, X., Zhang, Z., Su, W., Zhang, Y., Yu, Y., Li, Y., Zong, Z., & Yu, B. (2009) · Developmental Dynamics · doi:10.1002/dvdy.22131 · Cited by 10

Rapamycin regulates biochemical metabolites

Tucci, P., Porta, G., Agostini, M., Antonov, A., Garabadgiu, A. V., Melino, G., & Willis, A. E. (2013) · Cell Cycle · doi:10.4161/cc.25450 · Cited by 11

Latest developments in targeted therapy for hepatocellular carcinoma

Montella, L., Addeo, R., Caraglia, M., & Prete, S. D. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.146 · Cited by 10

Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin

Ahn, J., Woo, H., Ko, A., Khim, M., Kim, C., Park, N. H., Song, H. Y., Kim, S. W., & Lee, H. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0998-1 · Cited by 10

Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2

Xie, Y., Li, B., Bu, W., Gao, L., Zhang, Y., Lan, X., Hou, J., Xu, Z., Chang, S., Yu, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4438 · Cited by 10

Molecular targeting for treatment of advanced hepatocellular carcinoma

Song, I. H. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.299 · Cited by 10

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25